It will become more difficult to obtain cannabis in Luxembourg
Esteban López, Unsplash
Since legalisation in 2019, medical cannabis has become an important tool for treating patients with chronic pain, the effects of chemotherapy and spasms caused by multiple sclerosis. The programme is showing progress but requires refinement.
The decision to avoid cannabis flowers with a high THC content is due to several reasons. Firstly, the oil provides a more precise and stable dosage, which is difficult to achieve with flower inhalation. Studies have shown that the bioavailability of THC with flowers varies, making it difficult to control effects and increasing the risk of adverse reactions. Secondly, the potential for abuse of flowers (e.g. smoking them) makes oil extracts preferable.
Interestingly, the demand for extracts in Luxembourg has grown significantly. In 2022, only 18 bottles of oil extracts were prescribed, while in 2023 it was already more than 2,000, and in 2024 the figure passed 2,850.
From 1 January 2025, patients will be able to receive:
- Oil extracts with three cannabinoid profiles: THC-dominant, CBD-dominant and balanced.
- Cannabis flowers with high CBD content or a balanced ratio of THC to CBD.
The maximum tolerated dose for cannabis flowers over 28 days will be reduced from 100 grams to 60 grams, which is in line with the actual needs of patients.
To avoid disruptions in treatment, doctors and pharmacists have been given clear instructions. Patients are notified of changes at each visit, which is mandatory every 28 days. The last batch of high THC colours will be available until January 2025.
The first evaluation of the programme in 2022 identified the need for change. A new evaluation planned for 2025 will show how effective the measures taken have been.
